Apnex Medical touted a $10 million funding infusion from New Enterprise Associates, planning on using the money to support its ongoing clinical studies.
The St. Paul, Minn.-based respiratory devices company is amid clinical studies for its Hypoglossal Nerve Stimulation System for use in patients with obstructive sleep apnea.
The Apnex HGNS is an implantable device designed to delivery mild electrical stimulation to the muscles in the upper airway if it detects changes in a patient’s breathing. The shocks stimulate the muscles to keep the airway open, and can be programmed or manually operated to work only during sleep.
Apnex won FDA approval to launch its clinical trials to evaluate the safety and effectiveness of the HGNS system in order to collect data in support of pre-market approval, according to a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.